EICHOR
● Recruiting
A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients
Condition: CLL (Chronic Lymphocytic Leukemia) · Sponsor: The First Affiliated Hospital with Nanjing Medical University
About this study
This study is a prospective, multicenter, open-label, single-arm phase II clinical trial evaluating the efficacy and safety of an MRD-guided, time-limited therapy with zanubrutinib combined with sonrotoclax in previously untreated high-risk CLL/SLL patients.
This description comes directly from the study's public registry record.
Talk to the study team
Huayuan ZHU, MD, phD · +86-13813810650 · huayuan.zhu@hotmail.com
Always discuss trial participation with your own doctor first.
Locations (1)
| Jiangsu Province Hospital | Nanjing, Jiangsu, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07671378